

## **Announcement Summary**

# **Entity name**

PHARMAXIS LTD

#### Date of this announcement

Friday August 13, 2021

# The +securities the subject of this notification are:

## Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
PXSAAS	PERFORMANCE RIGHTS	4,055,600	12/08/2021

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

# 1.1 Name of entity

PHARMAXIS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

## 1.2 Registered number type

**Registration number** 

ABN

75082811630

#### 1.3 ASX issuer code

**PXS** 

## 1.4 The announcement is

☑ New announcement

#### 1.5 Date of this announcement

13/8/2021



#### Part 2 - Issue details

## 2.1 The +securities the subject of this notification are:

🗹 +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☑ has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities in an existing class issued under an +employee incentive scheme

#### ASX +security code and description

**PXSAAS: PERFORMANCE RIGHTS** 

Date the +securities the subject of this notification were issued

12/8/2021

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? 
⊗ Yes


Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
David McGarvey	same	471,600
Wolfgang Jarolimek	same	452,800
Brett Charlton	same	452,800
Kristen Morgan	same	297,200

# Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

- Grant Price Nil
- 2. Exercise Price Nil
- Expiry 30/6/31
- 4. Each Right entitles the holder to receive one fully paid ordinary share in PXS.
- Vesting
- a. At the end of the 2022 financial year the Board will assess achievement of objectives set by the Board for the 2022 year and lapse Rights to extent objectives were not achieved.
- b. 50% of remaining performance rights will vest and be exercisable at 30/6/23 and 30/6/24, provided that the holder is an employee.
- 6. Until 30/6/24, any shares acquired upon exercise of Rights may not be traded
- Any shares acquired upon exercise of Rights by Senior Executive Officers may only be traded with prior approval
  of the Board.

The Performance Rights are granted pursuant to, and subject to, the terms and conditions of the Pharmaxis Performance Rights Plan, a summary of which is available in the 2021 Annual Report of Pharmaxis available at <a href="https://www.pharmaxis.com.au">www.pharmaxis.com.au</a>





#### Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description

Total number of +securities on issue

PXS: ORDINARY FULLY PAID 452,924,164

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description

Total number of +securities on issue

PXSAG: OPTION EXPIRING 28-JUN-2022 EX NIL PRICE 92,000

PXSAAP: OPTION EXPIRING 06-JUN-2023 EX NIL PRICE 134,750

PXSAAS : PERFORMANCE RIGHTS 21,217,275



## Part 5 - Other Listing Rule requirements

- 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? ⊗ No
- 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

**☑** No

- 5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 
  ☑ Yes
- 5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

4055600

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? 
⊗ No